Moderna Inc
$ 25.49
1.23%
04 Dec - close price
- Market Cap 9,838,673,000 USD
- Current Price $ 25.49
- High / Low $ 25.89 / 24.70
- Stock P/E N/A
- Book Value 23.86
- EPS -8.44
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.29 %
- 52 Week High 48.92
- 52 Week Low 22.28
About
Moderna, Inc. is a pioneering biotechnology company based in Cambridge, Massachusetts, recognized for its innovative approach to messenger RNA (mRNA) technology in vaccine and therapeutic development. Gaining global prominence for its role in delivering one of the first successful COVID-19 vaccines, Moderna is now strategically expanding its portfolio to target a wide array of health challenges, including immuno-oncology, rare diseases, cardiovascular conditions, and autoimmune disorders. With a commitment to advancing healthcare through cutting-edge research and a strong product pipeline, Moderna seeks to redefine the future of medicine and address unmet medical needs on a global scale.
Analyst Target Price
$35.78
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-01 | 2025-04-30 | 2025-02-20 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 | 0.19 | 3.61 |
| Estimated EPS | -2.05 | -2.98 | -3.03 | -2.7599 | -1.9 | -3.38 | -3.58 | -0.97 | -1.93 | -4.04 | -1.77 | 4.68 |
| Surprise | 1.54 | 0.85 | 0.51 | -0.1501 | 1.93 | 0.05 | 0.51 | 1.52 | -7.6 | 0.42 | 1.96 | -1.07 |
| Surprise Percentage | 75.122% | 28.5235% | 16.8317% | -5.4386% | 101.5789% | 1.4793% | 14.2458% | 156.701% | -393.7824% | 10.396% | 110.7345% | -22.8632% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2025-12-04 16:10:12
Moderna (MRNA) has demonstrated a short-term bullish trend after crossing above its 20-day moving average, a key technical indicator for traders. The company also shows a strong positive outlook in earnings estimate revisions, with 9 upward revisions for the current fiscal year. Investors are encouraged to watch MRNA for potential further gains due to this combination of technical and fundamental strength.
2025-12-04 11:47:30
Norges Bank acquired 3,439,999 shares of Moderna, Inc. (NASDAQ:MRNA) valued at approximately $94.91 million during the second quarter, representing 0.88% of the company's stock. Other institutional investors also adjusted their holdings in Moderna, with 75.33% of the stock owned by hedge funds and institutions. The article also provides details on recent analyst ratings, share price performance, and Moderna's latest earnings report.
2025-12-04 11:47:30
Skandinaviska Enskilda Banken AB publ has significantly reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 98.5% in the second quarter, valuing their remaining 1,002 shares at $28,000. This move comes amidst other institutional investors modifying their holdings in Moderna, and various analysts issuing "Hold," "Buy," and "Sell" ratings for the stock, with a current consensus of "Reduce." Moderna recently reported better-than-expected quarterly earnings, though its revenue was down year-over-year.
2025-12-04 11:11:20
JPMorgan Chase & Co. reduced its stake in Wingstop Inc. (NASDAQ:WING) by 27.4% in the second quarter of 2025 by selling 27,335 shares, ending the period with 72,605 shares valued at $24.45 million. Despite this, other institutions increased their positions, and analysts maintain a "Moderate Buy" rating with a consensus target price of $335.96. Wingstop reported strong Q2 EPS of $1.09, beating estimates, and announced a quarterly dividend of $0.30 per share.
2025-12-04 01:23:48
This page provides financial data specifically focusing on the CapEx per share for Moderna, Inc. as traded on the Dusseldorf Stock Exchange under the ticker 0QF. It includes historical values and percentage changes for this metric over different periods. The page is part of TradingView's financial section, offering detailed statistics and ratios for the company.
2025-12-04 00:05:00
Jim Cramer recommends holding Pfizer (PFE), citing its growth potential in 2026 and its attractive 6.8% yield. He believes Pfizer's acquisitions, including Seagen and NURTEC, will strengthen its pipeline and help it overcome patent expirations and generate future growth, despite concerns from some investors. Cramer views Pfizer as a "bond equivalent" due to its high yield and potential turnaround.
